Neumora Therapeutics Inc. (NMRA) is at a crucial point this quarter as its lead drug candidate, Navacaprant, nears an important development milestone.
Navacaprant, also known as NMRA-140, is a highly selective, novel, once-daily kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for Major Depressive Disorder (MDD) and other neuropsychiatric disorders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com